Ophthalmology

Logistic regression analysis indicated that higher stages of urine albumin creatine ratio were significantly associated with diabetic retinopathy in patients with T2D and diabetic nephropathy.

The findings of a recent diagnostic study suggest that AI was able to infer the self-reported race of infants from retinal vessel maps, something human graders are unable to do.

A new study suggests ChatGPT may not provide substantial assistance in preparing for board certification at this time.

Pending FDA approval, RVO would be the third indication for faricimab-svoa in addition to wet age-related macular degeneration and diabetic macular edema.

The approval, granted to Eyenovia, Inc, represents the first-approved fixed-dose combination of tropicamide and phenylephrine for inducing mydriasis for diagnostic procedures and short-term pupil dilation.

Intravitreal steroid treatment for DME was associated with no significant differences in BCVA, but a higher risk of IOP-related events, compared to anti-VEGF therapy.

At ARVO 2023, Schmidt-Erfurth discusses new insights regarding disease activity in GA, observing reductions in both RPE and photoreceptor degeneration after intravitreal pegcetacoplan therapy in the OAKS and DERBY trials.

At ARVO 2023, Emanuelli discusses the primary analysis results of the phase 3 Pavilion trial evaluating the PDS with ranibizumab in patients with diabetic retinopathy without center-involved diabetic macular edema.

At ARVO 2023, Elizabeth Rossin, MD, PhD, elaborates on genetic and biological pathways that may contribute to epiretinal membrane risk.

A retrospective study of nearly 19,000 eyes presented at ARVO 2023 found patients with GA lost 2 lines of vision at year 3 and are at meaningful risk of nAMD.

At ARVO 2023, David Tabano, PhD, discussed the analysis of the largest real-world evaluation of treatment patterns and outcomes in DME patients treated with faricimab.

At ARVO 2023, Goldberg discusses how dual Ang-2/VEGF inhibition can provide greater vascular stability, which may contribute to faster fluid resolution and extended durability with faricimab treatment.

A personalized treat-and-extend–based regimen presented at ARVO 2023 suggested the long-term potential of faricimab to reduce the treatment burden for patients with DME.

Brandon Ayres, MD, provides an overview of lifitegrast efficacy and safety from the OPUS trials for the treatment of dry eye disease.

Laura Periman, MD, describes the mechanism of action of lifitegrast for the treatment of dry eye disease.

An analysis of the phase 2/3 PHOTON trial suggested the majority of patients with DME who received aflibercept 8 mg maintained 12- or 16-week dosing intervals.

At ARVO 2023, Do discusses the benefit of aflibercept 8 mg for DME in the phase 2/3 PHOTON trial, demonstrating non-inferiority in BCVA vs aflibercept 2 mg and no new safety concerns.

At ARVO 2023, Caroline Baumal, MD, chief medical officer of Apellis Pharmaceuticals, discussed new phase 3 functional analyses of pegcetacoplan injection, the future of the GA treatment landscape, and the next unmet need in ophthalmology.

An analysis of the STATUS program suggests the percentage of patients that received an annual eye exam increased from 65.2% to 72.8% in the clinics utilizing the IDx-DR system.

An analysis of the AlzEye study presented at ARVO 2023 suggests a deep-learning model showed promise in predicting three-year incident MACE using OCT.

An analysis of 118 infant eyes in India suggests the biosimilar is safe and effective in treating ROP, with about one-third of eyes requiring reinjection at 7 weeks after the first dose.

An analysis of an ethnically diverse cohort in London found African Caribbean people experienced a 39% greater risk of sight-threatening DR, independent of traditional risk factors.

The proportion of premature infants diagnosed with ROP increased from 4.4% in 2003 to 8.1% in 2019, particularly among underserved populations.

A retrospective analysis of more than 3 million patients who received the mRNA COVID-19 vaccine found no association between vaccination and newly diagnosed RVO.

According to Horizon Therapeutics, the updated indication language reinforces the importance of access for patients across the full spectrum of TED activity or duration.